Whereas previous reports mainly investigated YM155 in combination with taxanes to overcome chemoresistance in PC models [30] or identified survivin family members such as BIRC5 and BIRC7 as prognostic biomarkers through bioinformatic analyses [32], our work extends these findings by linking survivin expression to platinum response and by functionally validating the YM155–carboplatin synergy in AR-negative mCRPC models. Here, BIRC5 is linked to pachyonychia congenita.